Geron Corp (NASDAQ:GERN)
| CAPS Rating |
|
|---|---|
| Open | $2.02 |
| Previous Close | $2.05 |
| Daily Range | $1.98 - $2.05 |
| 52-Week Range | $1.35 - $5.24 |
| Market Cap | $262.19M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 614,700 |
| Average Daily Volume | 0 |
GERN
VS S&P 500 (SPY)
How do you think GERN will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
GERN Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
GERN News and Commentary
- Buy, Sell, or Hold: Geron – The Motley Fool
- Don't Bet Against This Biotech IPO – The Motley Fool
- Has GlaxoSmithKline Become the Perfect Stock? – The Motley Fool
- The focus will be on Stem Cells again.. – Blog at The Motley Fool
- Can Geron Recover in 2012? – The Motley Fool
- The Magic Formula for Biotech – The Motley Fool
- The Worst Health Care Stocks of 2011 – The Motley Fool
- Bullish Ideas: Short-Sellers Think These Cash-Rich Companies Have More Upside – The Motley Fool
- Health Care's Worst Stocks 2011: Dendreon – The Motley Fool
- Geron's Hurry-Up-and-Wait Strategy – The Motley Fool
- Whoa! My Stock Just Whupped the Market! – The Motley Fool
- If You Can't Beat 'Em, Join 'Em: Amgen Goes Generic – The Motley Fool
- What's Up With the Back-Slapping, Sequenom? – The Motley Fool
- Has Geron Become the Perfect Stock? – The Motley Fool
- In Drug Development, Help Is Crucial – The Motley Fool
- Breaking Down a Biotech Press Release – The Motley Fool
- Whoa! My Stock Just Crushed the Market! – The Motley Fool
- Market Volatility = Biotech Opportunity – The Motley Fool
- 5 Stocks Under $10 – The Motley Fool
- This Just In: More Upgrades and Downgrades – The Motley Fool
RSS Headlines
Fool UK
